Literature DB >> 10722424

National survey of extended-interval aminoglycoside dosing.

S K Chuck1, S R Raber, K A Rodvold, D Areff.   

Abstract

A random sample survey of 500 acute care hospitals in the United States was conducted to evaluate the adoption of extended-interval aminoglycoside dosing (EIAD). The survey revealed that EIAD has been adopted in 3 of every 4 acute care hospitals, a 4-fold increase since 1993. Of the 74.7% of hospitals reporting EIAD, 64% had written guidelines. Equal or less toxicity (87.1%), equal efficacy (76.9%), and cost-savings (65.6%) were common rationales. There has been a trend toward higher adult dosages of gentamicin (e.g., >5 mg/kg/dose) and an increase in the adoption of EIAD across all age groups (neonatal, 11%, and pediatric, 23%). Monitoring of aminoglycoside concentrations has shifted to a single determination of concentration, at 6-18 h after drug administration. The most common methods of dosage adjustment for declining renal function were an interval extension with the same dose (47%) or use of the Hartford nomogram (32%).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722424     DOI: 10.1086/313692

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants.

Authors:  M English; S Mohammed; A Ross; S Ndirangu; G Kokwaro; F Shann; K Marsh
Journal:  Arch Dis Child       Date:  2004-07       Impact factor: 3.791

2.  Individualising netilmicin dosing in neonates.

Authors:  Catherine M T Sherwin; Roland S Broadbent; Natalie J Medlicott; David M Reith
Journal:  Eur J Clin Pharmacol       Date:  2008-08-07       Impact factor: 2.953

3.  Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies.

Authors:  Tze-Peng Lim; Kevin W Garey; Vincent H Tam
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

4.  Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Samer Kabbara; Giao Vo; Amy N Schilling; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 5.  One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.

Authors:  Shripada C Rao; Ravisha Srinivasjois; Kwi Moon
Journal:  Cochrane Database Syst Rev       Date:  2016-12-06

6.  Application of guidelines for aminoglycosides use in French hospitals in 2013-2014.

Authors:  J Robert; Y Péan; S Alfandari; J-P Bru; J-P Bedos; C Rabaud; R Gauzit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-09       Impact factor: 3.267

7.  Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection.

Authors:  Tomefa E Asempa; Joseph L Kuti; Julie D Seroogy; Allison S Komirenko; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

8.  Population pharmacokinetics of intramuscular gentamicin administered to young infants with suspected severe sepsis in Kenya.

Authors:  Alison H Thomson; Gilbert O Kokwaro; Simon N Muchohi; Michael English; Shebbe Mohammed; Geoffrey Edwards
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

9.  High-Dose, Extended-Interval Gentamicin and Tobramycin for Pediatric Inpatients: A Survey of Canadian Hospital Pharmacists.

Authors:  Caitlin Roy; Carolyn Gray; Lisa Ruda; Ali Bell; Jennifer Bolt
Journal:  Can J Hosp Pharm       Date:  2016-10-31

Review 10.  Clinical pharmacokinetics of aminoglycosides in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Eur J Clin Pharmacol       Date:  2008-12-23       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.